Department Metrics

• 2/2 Ponce Health Sciences University-Moffitt Cancer Center Partnership
  Sponsor: Nat Institutes of Health
  PI (Contact):Wright, K.,PI (MPI):Monteiro, A.
• Augmenting T Cell Trafficking and Functionality through Novel Combinations of Epigenetic Agents and PD-1 Blockade
  Sponsor: Nat Institutes of Health
  PI:Beg, A.
• Regulation of dendritic cell function and tumor immunity by TIM-3
  Sponsor: Nat Institutes of Health
  PI:Ruffell, B.
• Reprogramming Transmembrane ubiquitin Ligases To Control Cell Surface Receptor Landscapes.
  Sponsor: Rita Allen Foundation
  PI:Luca, V.
• Functional reprogramming of tumor-MDSC through antibody-based therapies Targeting Notch Ligands
  Sponsor: Nat Institutes of Health
  PI:Rodriguez, P.
• Imaging Acidosis and Immune Therapy in PDAC
  Sponsor: Nat Institutes of Health
  PI (Contact):Pilon-Thomas, S.,PI:Ibrahim Hashim, A.
• Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering
  Sponsor: Nat Institutes of Health
  PI:Luca, V.
• Illuminating Notch receptor-ligand selectivity through structure-guided protein engineering
  Sponsor: Nat Institutes of Health
  PI:Luca, V.
• Understanding the influence of bone-metastatic prostate cancer and mesenchymal stromal cells on γδ T cells, in the bone microenvironment.
  Sponsor: Nat Institutes of Health
  PI (Contact):Abate-Daga, D.
• Research Plan A-3: NSG Mouse Models to Evaluate the Efficacy of TIL
  Sponsor: Iovance Biotherapeutics
  PI:Pilon-Thomas, S.
• Role of Bcl11b in CD4+ T Cells and Innate Lymphoid Cells
  Sponsor: Nat Institutes of Health
  PI:Avram, D.
• High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase implicated in multiple sclerosis
  Sponsor: Nat Institutes of Health
  PI (MPI):Avram, D.
• Directing Tryptophan Immunometabolism to Ameliorate Liver Ischemic-Reperfusion Injury
  Sponsor: Nat Institutes of Health
  PI:Avram, D.
• Bile acids restrict functional reprogramming of myeloid-derived suppressor cells in tumor beds
  Sponsor: Nat Institutes of Health
  PI:Rodriguez, P.
• Plant-derived extracts regulate immunosuppressive myelopoiesis in Breast cancer patients
  Sponsor: Nat Institutes of Health
  PI:Rodriguez, P.
• Engineering Bispecific Nanobodies for Detection of Breast Cancer Nodal Metastasis
  Sponsor: US Army
  PI:Luca, V.
• Institutional Research Grant - Moffitt Cancer Center
  Sponsor: Amer Cancer Society
  PI:Wright, K.
• Platinum-induced lipid reprogramming and tumor immune microenvironment in SCLC
  Sponsor: Nat Institutes of Health
  PI:Avram, D.
• Study of Anti-Tumor Immunity and Tissue Resident Memory Cell Development by NKG2D and Ribosomal Protein S6 Signaling in T cells
  Sponsor: Nat Institutes of Health
  PI:Guevara, J.
• Development of Adoptive T-Cell Therapy in Bladder Cancer Incorporating Patient-Specific Tumor Microenvironment
  Sponsor: US Army
  PI:Pilon-Thomas, S.
• Structure-guided engineering of LAG3 immunomodulatory function
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Luca, V.
• Targeting ENPP1 to promote immunity during PARP inhibition in TNBC
  Sponsor: US Army
  PI (Contact):Ruffell, B.
• Targeting ENPP1 to promote immunity during PARP inhibition in TNBC
  Sponsor: US Army
  PI:Luca, V.
• Transdermal Alkalinization Treatment as an Adjunct in Melanoma Therapy
  Sponsor: Dyve Biosciences
  PI:Pilon-Thomas, S.,CO-PI:Gillies, R.
• Tissue-Anchored vs. Circulating Constructs for Immunometabolic Resolution of Psoriasis
  Sponsor: Nat Institutes of Health
  PI (MPI):Avram, D.
• Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors
  Sponsor: Nat Institutes of Health
  PI:Rodriguez, P.
• The Role of Hypoxia on Tumor Infiltrating Lymphocytes (TIL) from Renal Cell Carcinoma (RCC)
  Sponsor: US Army
  PI:Pilon-Thomas, S.
• Exploratory Study of T Cell Skin Trafficking and the Role of NKG2D Signaling; Implications in Vitiligo and Melanoma
  Sponsor: Nat Institutes of Health
  PI:Guevara, J.
• Targeting dendritic cells to improve cancer immunotherapy
  Sponsor: Cancer Research Institute
  PI:Ruffell, B.
• KIR2DL2 Immune Checkpoint as Modulator of T-Cell Effector Function
  Sponsor: Nat Institutes of Health
  PI:Abate-Daga, D.
• Metabolic and molecular regulation of myeloid cell functions in brain cancer
  Sponsor: Nat Institutes of Health
  PI:Veglia, F.
• Improving melanoma immunotherapy through connections of TLSs, TIL, STING, and MARCO
  Sponsor: Adelson (Miriam & Sheldon) Medical Res Fdtn
  PI:Mulé, J.
• CD3z-Independent Signaling Module for CAR-T Cell Therapies Against Solid Cancer
  Sponsor: Florida Biomedical Research Program (FBRP)
  PI:Guevara, J.
• Defining Impact of in SITU Activation of CD40 and Type 1 Interferon Signaling on theTME and Systemic T Cell Immunity in Murine models and cancer patients
  Sponsor: Nat Institutes of Health
  PI:Beg, A.
• Research Plan 8: Expansion, Enrichment, and Confirmation of Neoantigen Reactive TILS from GI/CRC tumors, selection of TILS reactive to patient-tumor neoantigens, and characterization of their reactivity and tumor cell killing capabilities
  Sponsor: Turnstone Biologics
  PI:Pilon-Thomas, S.
• Research Plan 9: Optimize the Turnstone process.
  Sponsor: Turnstone Biologics
  PI:Pilon-Thomas, S.
• Structure and Biophysics of CD24 Interactions
  Sponsor: Pheast Therapeutics
  PI:Luca, V.
• Predict radiation-induced shifts in patient-specific tumor immune ecosystem composition to harness immunological consequences of radiotherapy
  Sponsor: Nat Institutes of Health
  PI:Pilon-Thomas, S.
• Comparative Analysis of a novel TRP1-NKG2D CAR-T Cells Versus 2nd Generation CARs in Melanoma
  Sponsor: Moffitt Cancer Center
  PI:Guevara, J.
• Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) is a promising form of T cell-based immunotherapy.
  Sponsor: Moffitt Fdtn
  PI:Pilon-Thomas, S.
• Research Plan 10: Continued Analysis of Biological Specimens for the Turnstone Process
  Sponsor: Turnstone Biologics
  PI:Pilon-Thomas, S.

CLINICAL TRIAL 19724
Managed Access Program (MAP) To Provide Access To CTL019, For Acute Lymphoblastic Leukemia (ALL) Or Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Out Of Specification Leukapheresis Product And/Or Manufactured Tisagenlecleucel Out Of Specification For Commercial Release
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 20578
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmocodynamics of ALLO-501A, an Anti-CD19 Allogeneic Car T Cell Therapy in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Condition: Malignant Hematology
Intervention: ALLO-501 (); ALLO-501A (); ALLO-647 (); Not Applicable (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 20571
Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination with Pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T-cell Immunotherapy
Condition: Immunotherapy
Intervention: CD19 CAR T Cells (); PCV13 ()

CLINICAL TRIAL 20737
Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release
Condition: Malignant Hematology
Intervention: cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); lisocabtagene maraleucel ()

CLINICAL TRIAL 20794
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: Safety and Biomarker Analysis
Condition: Cutaneous
Intervention: Cemiplimab (); REGN2810 (Cemiplimab)

CLINICAL TRIAL 20923
A Phase I/II Trial of Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
Condition: Malignant Hematology
Intervention: Fedratinib ()

CLINICAL TRIAL 20955
A Phase II Study of Binimetinib plus Belinostat for Subjects with Metastatic Uveal Melanoma
Condition: Cutaneous
Intervention: Belinostat (); Binimetinib (); PXD101 (Belinostat)

CLINICAL TRIAL 21239
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (Opdivo); Sargramostim (); Yervoy (Ipilimumab)

CLINICAL TRIAL 21341
A Phase II Study of Cemiplimab plus Ziv-Aflibercept for Subjects with Metastatic Uveal Melanoma
Condition: Cutaneous
Intervention: Cemiplimab (); REGN2810 (Cemiplimab); Ziv-aflibercept ()

CLINICAL TRIAL 21340
A First-In-Human, Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 With or Without Obinutuzumab Pre-treatment, and ST-067 in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies
Condition: Multiple
Intervention: Obinutuzumab (); Pembrolizumab (Keytruda); ST-067 ()

CLINICAL TRIAL 21366
Administration of HIV-specific T Cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue -Auto-RESIST
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); Carmustine (); Cytarabine (Cytosine Arabinoside); Melphalan (); etoposide ()

CLINICAL TRIAL 21452
Evaluating Gut Microbiome As A Biomarker Of Pathological Complete Response In Patients With Early Triple Negative Breast Cancer - A Pilot Study (TCC)
Condition: Breast
Intervention:

CLINICAL TRIAL 21623
A Phase 1/2 Study of bbT369, a Dual Targeting CAR T cell Drug Product with a Gene Edit, in Relapsed and/or Refractory B cell Non-Hodgkin s Lymphoma
Condition: Immunotherapy
Intervention: Lymphodepletion (); bbT369 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 21690
A Phase 1b, Single Arm Study of CG0070 after Transurethral Resection in Patients with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Condition: Genitourinary
Intervention: CG0070 (); DDM ()

CLINICAL TRIAL 21887
A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes
Condition: Malignant Hematology
Intervention: ASTX727 (); Itacitinib ()

CLINICAL TRIAL 21894
Phase 1 Clinical Trial of lntravesical Adoptive Cell Therapy {ACT) with Tumor Infiltrating Lymphocytes (TIL) for Patients with BCG Exposed High Grade Non-Muscle Invasive Bladder Cancer {NMIBC)
Condition: Genitourinary
Intervention:

CLINICAL TRIAL 22009
CTNO155X2101: An Open-Label, Multi-Center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients with Advanced Solid Tumors
Condition: Cutaneous
Intervention: TNO155 ()

CLINICAL TRIAL 22294
A Randomized Phase III Study of Neoadjuvant Chemotherapy followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
Condition: Sarcoma
Intervention: Adriamycin (doxorubicin); DTIC (Dacarbazine); Dacarbazine (); Ifosfamide (); Not Applicable (); doxorubicin ()

CLINICAL TRIAL 22349
Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions
Condition: Genitourinary
Intervention: JNJ-42756493 (Erdafitinib)

CLINICAL TRIAL 22367
The Impact Of Inflammation On HSPC Composition And Disease Progression In Chronic Myelomonocytic Leukemia (CMML INTERCEPT STUDY) SUB-TITLE: Intercepting CMML Disease Progression Driven by Acute Inflammation
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 22574
Biomarker Driven Patient Selection for Neoadjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma: A Pilot Study
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); BMS-986016 (Relatlimab); Ipilimumab (); Nivolumab (Opdivo); Relatlimab (); Yervoy (Ipilimumab)

• Burton C, Bitaraf A, Snyder K, Zhang C, Yoder SJ, Avram D, Du D, Yu X, Lau EK. The functional role of L-fucose on dendritic cell function and polarization. Front Immunol. 2024 Apr.15:1353570. Pubmedid: 38646527. Pmcid: PMC11026564.
• Markowitz J, Shamblott M, Brohl AS, Sarnaik AA, Eroglu Z, Khushalani NI, Dukes CW, Chamizo A, Bastawrous M, Garcia ET, Delhawi A, Chen PL, De Aquino DB, Sondak VK, Tarhini AA, Kim Y, Lawman P, Pilon-Thomas S. First-in-human stage III/IV melanoma​ clinical trial of immune priming agent IFx-Hu2.0. Mol Cancer Ther. 2024 Apr. Pubmedid: 38657233.
• Conejo-Garcia JR, Rodriguez PC. Introduction to the special issue: B cells in cancer immunosurveillance. Semin Immunol. 2024 Mar.72:101866. Pubmedid: 38442534.
• Faramand RG, Lee SB, Jain MD, Cao B, Wang X, Rejeski K, Subklewe M, Fahrmann JF, Saini NY, Hanash SM, Kang YP, Chang D, Rodriguez PC, Dean EA, Nishihori T, Shah BD, Lazaryan A, Chavez J, Khimani F, Pinilla-Ibarz JA, Dam M, Reid KM, Corallo SA, Menges M, Hidalgo Vargas M, Mandula JK, Holliday BA, Bachmeier CA, Speth K, Song Q, Mattie M, Locke FL, Davila ML. Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma. Blood Cancer Discov. 2024 Mar.5(2):106-113. Pubmedid: 38194367. Pmcid: PMC10905320.
• Stewart MD, Kalos M, Coutinho V, Better M, Jazayeri J, Yohrling J, Jadlowsky J, Fuchs M, Gidwani S, Goessl C, Hanley PJ, Healy J, Liu W, McKelvey BA, Pearce L, Pilon-Thomas S, Andrews HS, Veldman M, Vong J, Weinbach SP, Allen JD. Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products. Cytotherapy. 2024 Mar. Pubmedid: 38583170.
• Ojwang' AME, Bazargan S, Johnson JO, Pilon-Thomas S, Rejniak KA. Histology-guided mathematical model of tumor oxygenation: sensitivity analysis of physical and computational parameters. bioRxiv. 2024 Mar. Pubmedid: 38496532. Pmcid: PMC10942376.
• Swietach P, Jäättelä M, Pilon-Thomas S, Boedtkjer E. Carnosine facilitates lysosomal release of inhibitors of T cell surveillance. Cell Metab. 2024 Mar.36(3):461-462. Pubmedid: 38447528.
• Jardim-Perassi BV, Irrera P, Oluwatola OE, Abrahams D, Estrella VC, Ordway B, Byrne SR, Ojeda AA, Whelan CJ, Kim J, Beatty MS, Damgaci-Erturk S, Longo DL, Gaspar KJ, Siegers GM, Centeno BA, Lau JYC, Pilon-Thomas SA, Ibrahim-Hashim A, Gillies RJ. L-DOS47 Elevates Pancreatic Cancer Tumor pH and Enhances Response to Immunotherapy. Biomedicines. 2024 Feb.12(2). Pubmedid: 38398062. Pmcid: PMC10886509.
• Ibrahim ML, Zheng H, Barlow ML, Latif Y, Chen Z, Yu X, Beg AA. Histone Deacetylase Inhibitors Directly Modulate T Cell Gene Expression and Signaling and Promote Development of Effector-Exhausted T Cells in Murine Tumors. J Immunol. 2024 Feb.212(4):737-747. Pubmedid: 38169329. Pmcid: PMC10872871.
• Perez C, Plaza-Rojas L, Boucher JC, Nagy MZ, Kostenko E, Prajapati K, Burke B, Reyes MD, Austin AL, Zhang S, Le PT, Guevara-Patino JA. NKG2D receptor signaling shapes T cell thymic education. J Leukoc Biol. 2024 Jan.115(2):306-321. Pubmedid: 37949818.
• Smyrlaki I, Fördős F, Rocamonde-Lago I, Wang Y, Shen B, Lentini A, Luca VC, Reinius B, Teixeira AI, Högberg B. Soluble and multivalent Jag1 DNA origami nanopatterns activate Notch without pulling force. Nat Commun. 2024 Jan.15(1):465. Pubmedid: 38238313. Pmcid: PMC10796381.
• Hwang SM, Awasthi D, Jeong J, Sandoval TA, Chae CS, Ramos Y, Tan C, Falco MM, McBain IT, Mishra B, Ivashkiv LB, Zamarin D, Cantillo E, Chapman-Davis E, Holcomb K, Morales DK, Rodriguez PC, Conejo-Garcia JR, Kaczocha M, Vähärautio A, Song M, Cubillos-Ruiz JR. Transgelin 2 guards T cell lipid metabolic programming and anti-tumor function. Res Sq. 2023 Dec. Pubmedid: 38168227. Pmcid: PMC10760247.
• Khaled ML, Ren Y, Kundalia R, Alhaddad H, Chen Z, Wallace GC, Evernden B, Ospina OE, Hall M, Liu M, Darville LNF, Izumi V, Chen YA, Pilon-Thomas S, Stewart PA, Koomen JM, Corallo SA, Jain MD, Robinson TJ, Locke FL, Forsyth PA, Smalley I. Branched-chain keto acids promote an immune-suppressive and neurodegenerative microenvironment in leptomeningeal disease. bioRxiv. 2023 Dec. Pubmedid: 38187773. Pmcid: PMC10769272.
• Dukes CW, Potez M, Lancet J, Kuter BJ, Whiting J, Mo Q, Leav B, Wang H, Vanas JS, Cubitt CL, Isaacs-Soriano K, Kennedy K, Rathwell J, Diaz Cobo J, O'Nan W, Sirak B, Dong N, Tan E, Hwu P, Giuliano AR, Pilon-Thomas S. Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients. Vaccines (Basel). 2023 Dec.12(1). Pubmedid: 38250826. Pmcid: PMC10818923.
• Eisa NH, Crowley VM, Elahi A, Kommalapati VK, Serwetnyk MA, Llbiyi T, Lu S, Kainth K, Jilani Y, Marasco D, El Andaloussi A, Lee S, Tsai FTF, Rodriguez PC, Munn D, Celis E, Korkaya H, Debbab A, Blagg B, Chadli A. Enniatin A inhibits the chaperone Hsp90 and unleashes the immune system against triple-negative breast cancer. iScience. 2023 Dec.26(12):108308. Pubmedid: 38025772. Pmcid: PMC10663837.
• Phadke MS, Li J, Chen Z, Rodriguez PC, Mandula JK, Karapetyan L, Forsyth PA, Chen YA, Smalley KSM. Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models. J Immunother Cancer. 2023 Dec.11(12). Pubmedid: 38056899. Pmcid: PMC10711842.
• Boucher JC, Shrestha B, Vishwasrao P, Leick M, Cervantes EV, Ghafoor T, Reid K, Spitler K, Yu B, Betts BC, Guevara-Patino JA, Maus MV, Davila ML. Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Mol Ther Oncolytics. 2023 Dec.31:100751. Pubmedid: 38075241. Pmcid: PMC10701585.
• Medina E, Perez DH, Antfolk D, Luca VC. New tricks for an old pathway: emerging Notch-based biotechnologies and therapeutics. Trends Pharmacol Sci. 2023 Dec.44(12):934-948. Pubmedid: 37891017.
• Feng Y, Yuan Q, Newsome RC, Robinson T, Bowman RL, Zuniga AN, Hall KN, Bernsten CM, Shabashvili DE, Krajcik KI, Gunaratne C, Zaroogian ZJ, Venugopal K, Casellas Roman HL, Levine RL, Chatila WK, Yaeger R, Riva A, Jobin C, Kopinke D, Avram D, Guryanova OA. Hematopoietic-specific heterozygous loss of Dnmt3a exacerbates colitis-associated colon cancer. J Exp Med. 2023 Nov.220(11). Pubmedid: 37615936. Pmcid: PMC10450614.
• Soupir AC, Hayes MT, Peak TC, Ospina O, Chakiryan NH, Berglund AE, Stewart PA, Nguyen J, Segura CM, Francis NL, Echevarria PMR, Chahoud J, Li R, Tsai KY, Balasi JA, Peres YC, Dhillon J, Martinez LA, Gloria WE, Schurman N, Kim S, Gregory M, Mulé J, Fridley BL, Manley BJ. Increased spatial coupling of integrin and collagen IV in the immunoresistant clear cell renal cell carcinoma tumor microenvironment. bioRxiv. 2023 Nov. Pubmedid: 38014063. Pmcid: PMC10680839.
• Haubner S, Mansilla-Soto J, Nataraj S, Kogel F, Chang Q, de Stanchina E, Lopez M, Ng MR, Fraser K, Subklewe M, Park JH, Wang X, Rivière I, Sadelain M. Cooperative CAR targeting to selectively eliminate AML and minimize escape. Cancer Cell. 2023 Nov.41(11):1871-1891.e6. Pubmedid: 37802054.
• Biswas S, Mandal G, Anadon CM, Chaurio RA, Lopez-Bailon LU, Nagy MZ, Mine JA, Hänggi K, Sprenger KB, Innamarato P, Harro CM, Powers JJ, Johnson J, Fang B, Eysha M, Nan X, Li R, Perez BA, Curiel TJ, Yu X, Rodriguez PC, Conejo-Garcia JR. Targeting intracellular oncoproteins with dimeric IgA promotes expulsion from the cytoplasm and immune-mediated control of epithelial cancers. Immunity. 2023 Nov.56(11):2570-2583.e6. Pubmedid: 37909039. Pmcid: PMC10703011.
• Hall MS, Teer JK, Yu X, Branthoover H, Snedal S, Rodriguez-Valentin M, Nagle L, Scott E, Schachner B, Innamarato P, Hall AM, Blauvelt J, Rich CJ, Richards AD, Ceccarelli J, Langer TJ, Yoder SJ, Beatty MS, Cox CA, Messina JL, Abate-Daga D, Mule JJ, Mullinax JE, Sarnaik AA, Pilon-Thomas S. Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients. J Immunother Cancer. 2023 Oct.11(10). Pubmedid: 37802604. Pmcid: PMC10565316.
• Bazargan S, Bunch B, Ojwang' AME, Blauvelt J, Landin A, Ali J, Abrahams D, Cox C, Hall AM, Beatty MS, Poch M, Rejniak KA, Pilon-Thomas S. Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer. Front Immunol. 2023 Oct.14:1275375. Pubmedid: 37901214. Pmcid: PMC10602731.
• Bracho-Sanchez E, Rocha FG, Bedingfield SK, Partain BD, Macias SL, Brusko MA, Colazo JM, Fettis MM, Farhadi SA, Helm EY, Koenders K, Kwiatkowski AJ, Restuccia A, Morales BS, Wanchoo A, Avram D, Allen KD, Duvall CL, Wallet SM, Hudalla GA, Keselowsky BG. Suppression of local inflammation via galectin-anchored indoleamine 2,3-dioxygenase. Nat Biomed Eng. 2023 Sep.7(9):1156-1169. Pubmedid: 37127708. Pmcid: PMC10504068.
• Elmarsafawi AG, Hesterberg RS, Fernandez MR, Yang C, Darville LN, Liu M, Koomen JM, Phanstiel Iv O, Atkins R, Mullinax JE, Pilon-Thomas SA, Locke FL, Epling-Burnette PK, Cleveland JL. Modulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cells. JCI Insight. 2023 Sep.8(18). Pubmedid: 37581943. Pmcid: PMC10561731.
• Dukes CW, Rossetti RA, Hensel JA, Snedal S, Cubitt CL, Schell MJ, Abrahamsen M, Isaacs-Soriano K, Kennedy K, Mangual LN, Whiting J, Martinez-Brockhus V, Islam JY, Rathwell J, Beatty M, Hall AM, Abate-Daga D, Giuliano AR, Pilon-Thomas S. SARS-CoV-2 antibody response duration and neutralization following natural infection. J Clin Virol Plus. 2023 Aug.3(3). Pubmedid: 37654784. Pmcid: PMC10470471.
• Jhawar SR, Wang SJ, Thandoni A, Bommareddy PK, Newman JH, Marzo AL, Kuzel TM, Gupta V, Reiser J, Daniels P, Schiff D, Mitchell D, LeBoeuf NR, Simmons C, Goyal S, Lasfar A, Guevara-Patino JA, Haffty BG, Kaufman HL, Silk AW, Zloza A. Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer. J Immunother Cancer. 2023 Jul.11(7). Pubmedid: 37433716. Pmcid: PMC10347455.
• Lockhart JH, Ackerman HD, Lee K, Abdalah M, Davis AJ, Hackel N, Boyle TA, Saller J, Keske A, Hänggi K, Ruffell B, Stringfield O, Cress WD, Tan AC, Flores ER. Grading of lung adenocarcinomas with simultaneous segmentation by artificial intelligence (GLASS-AI). NPJ Precis Oncol. 2023 Jul.7(1):68. Pubmedid: 37464050. Pmcid: PMC10354042.
• Tometich DB, Hoogland AI, Small BJ, Janelsins MC, Bryant C, Rodriguez Y, Gonzalez BD, Li X, Bulls HW, James BW, Arboleda B, Colon-Echevarria C, Townsend MK, Tworoger SS, Rodriguez P, Oswald LB, Bower JE, Apte SM, Wenham RM, Chon HS, Shahzad MM, Jim HSL. Relationships among Inflammatory Biomarkers and Objectively Assessed Physical Activity and Sleep during and after Chemotherapy for Gynecologic Malignancies. Cancers (Basel). 2023 Jul.15(15). Pubmedid: 37568698. Pmcid: PMC10416903.
• Singh AM, Guevara-Patino JA, Wang X, Li R, Sonpavde G, Jain RK. Antibody-Drug Conjugates in the Treatment of Urothelial Cancer. BioDrugs. 2023 Jul.37(4):505-520. Pubmedid: 37256534.
• Giuliano A, Kuter B, Pilon-Thomas S, Whiting J, Mo Q, Leav B, Sirak B, Cubitt C, Dukes C, Isaacs-Soriano K, Kennedy K, Ball S, Dong N, Jain A, Hwu P, Lancet J. Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients. Cancer Commun (Lond). 2023 Jul.43(7):749-764. Pubmedid: 37377402. Pmcid: PMC10354405.
• Odak A, Yuan H, Feucht J, Cantu VA, Mansilla-Soto J, Kogel F, Eyquem J, Everett J, Bushman FD, Leslie CS, Sadelain M. Novel extragenic genomic safe harbors for precise therapeutic T-cell engineering. Blood. 2023 Jun.141(22):2698-2712. Pubmedid: 36745870. Pmcid: PMC10273162.
• Obermayer AN, Chang D, Nobles G, Teng M, Tan AC, Wang X, Chen YA, Eschrich S, Rodriguez PC, Grass GD, Meshinchi S, Tarhini A, Chen DT, Shaw TI. PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing. BMC Bioinformatics. 2023 Jun.24(1):266. Pubmedid: 37380943. Pmcid: PMC10303868.
• Hoogland AI, Small BJ, Oswald LB, Bryant C, Rodriguez Y, Gonzalez BD, Li X, Janelsins MC, Bulls HW, James BW, Arboleda B, Colon-Echevarria C, Townsend MK, Tworoger SS, Rodriguez PC, Bower JE, Apte SM, Wenham RM, Jim HSL. Relationships among Inflammatory Biomarkers and Self-Reported Treatment-Related Symptoms in Patients Treated with Chemotherapy for Gynecologic Cancer: A Controlled Comparison. Cancers (Basel). 2023 Jun.15(13). Pubmedid: 37444517. Pmcid: PMC10340589.
• Chaudhary R, Slebos RJC, Noel LC, Song F, Poole MI, Hoening DS, Hernandez-Prera JC, Conejo-Garcia JR, Guevara-Patino JA, Wang X, Xie M, Tan AC, Chung CH. EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma. Cancer Res Commun. 2023 May.3(5):896-907. Pubmedid: 37377902. Pmcid: PMC10202124.
• Hänggi K, Ruffell B. Cell death, therapeutics, and the immune response in cancer. Trends Cancer. 2023 May.9(5):381-396. Pubmedid: 36841748. Pmcid: PMC10121860.
• Frieling JS, Tordesillas L, Bustos XE, Ramello MC, Bishop RT, Cianne JE, Snedal SA, Li T, Lo CH, de la Iglesia J, Roselli E, Benzaïd I, Wang X, Kim Y, Lynch CC, Abate-Daga D. γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer. Sci Adv. 2023 May.9(18):eadf0108. Pubmedid: 37134157. Pmcid: PMC10156127.